Correlation Between UroGen Pharma and Fortress Biotech

Can any of the company-specific risk be diversified away by investing in both UroGen Pharma and Fortress Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining UroGen Pharma and Fortress Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between UroGen Pharma and Fortress Biotech Pref, you can compare the effects of market volatilities on UroGen Pharma and Fortress Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in UroGen Pharma with a short position of Fortress Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of UroGen Pharma and Fortress Biotech.

Diversification Opportunities for UroGen Pharma and Fortress Biotech

0.42

Correlation Coefficient

UroGen Pharma  Fortress Biotech

Very weak diversification

The 3 months correlation between UroGen and Fortress is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding UroGen Pharma and Fortress Biotech Pref in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Fortress Biotech Pref and UroGen Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on UroGen Pharma are associated (or correlated) with Fortress Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Fortress Biotech Pref has no effect on the direction of UroGen Pharma i.e., UroGen Pharma and Fortress Biotech go up and down completely randomly.

Pair Corralation between UroGen Pharma and Fortress Biotech

Given the investment horizon of 90 days UroGen Pharma is expected to generate 1.05 times more return on investment than Fortress Biotech. However, UroGen Pharma is 1.05 times more volatile than Fortress Biotech Pref. It trades about 0.05 of its potential returns per unit of risk. Fortress Biotech Pref is currently generating about -0.02 per unit of risk. If you would invest  1,052  in UroGen Pharma on December 30, 2024 and sell it today you would earn a total of  68.00  from holding UroGen Pharma or generate 6.46% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

UroGen Pharma  vs.  Fortress Biotech Pref

UroGen Pharma

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in UroGen Pharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating technical and fundamental indicators, UroGen Pharma may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Fortress Biotech Pref

Risk-Adjusted Performance

Very Weak

Over the last 90 days Fortress Biotech Pref has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Fortress Biotech is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with UroGen Pharma and Fortress Biotech

The main advantage of trading using opposite UroGen Pharma and Fortress Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if UroGen Pharma position performs unexpectedly, Fortress Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will offset losses from the drop in Fortress Biotech's long position.

The idea behind UroGen Pharma and Fortress Biotech Pref pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.